Alterity Therapeutics バランスシートの健全性

財務の健全性基準チェック /56

Alterity Therapeuticsの総株主資本はA$13.8M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$19.2MとA$5.4Mです。

主要情報

負債資本比率

AU$0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	AU$12.64m
エクイティ	AU$13.80m
負債合計	AU$5.43m
総資産	AU$19.22m

財務の健全性に関する最新情報

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

財務状況分析

短期負債: ATHEの短期資産 ( A$19.0M ) が短期負債 ( A$5.4M ) を超えています。

長期負債: ATHEの短期資産 ( A$19.0M ) が長期負債 ( A$51.9K ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: ATHEは負債がありません。

負債の削減: ATHE 5 年前には負債がありませんでした。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: ATHEは、現在のフリーキャッシュフローに基づき、1 年以上にわたって十分なキャッシュランウェイを有しています。

キャッシュランウェイの予測: ATHEのフリーキャッシュフローが過去のレートに基づいて増加または減少し続ける場合、十分なキャッシュランウェイがあるかどうかを判断するためのデータが不十分です。

Alterity Therapeutics バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Alterity Therapeutics Limited Announces Management Changes

Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

Alterity Therapeutics names Dr. David Stamler as CEO

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study

Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /56